Critical assessment of angiogenesis inhibitors in clinical trials.

被引：0
|
作者：
Eskens, F [1 ]
机构：
[1] Univ Rotterdam Hosp, Rotterdam, Netherlands
来源：
CLINICAL CANCER RESEARCH | 2001年 / 7卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P808
引用
收藏
页码：3816S / 3816S
页数：1
相关论文
共 50 条
  • [1] Critical assessment of angiogenesis inhibitors in clinical trials
    Eskens, F
    TUMORI, 2002, : S12 - S13
  • [2] Quality of life assessment in clinical trials.
    Cramer, JA
    EPILEPSIA, 1999, 40 : 214 - 214
  • [3] Clinical trials to begin on potent angiogenesis inhibitors
    Abbasi, K
    BRITISH MEDICAL JOURNAL, 1998, 316 (7142): : 1407 - 1407
  • [4] Choosing geriatric assessment tools for elderly in clinical trials.
    Rodin, MB
    Gupta, S
    Kuball, K
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 434S - 434S
  • [5] Ancient clinical trials.
    Lewis, EJ
    NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (01): : 83 - 84
  • [6] Glycitein for clinical trials.
    Verbruggen, MA
    Olieman, K
    JOURNAL OF NUTRITION, 2002, 132 (03): : 601S - 601S
  • [7] ACE inhibitors and cardiac arrhythmia: Analysis of design and outcomes of clinical trials.
    Yacine, A
    Tarasova, O
    AMERICAN JOURNAL OF HYPERTENSION, 1999, 12 (04) : 145A - 145A
  • [8] Transforming the site feasibility assessment process for oncology clinical trials.
    Kurbegov, Dax
    Hurley, Patricia A.
    Waterhouse, David Michael
    Nowakowski, Grzegorz S.
    Kim, Edward S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [9] Advancement in KRAS clinical trials.
    Yeung, Wayne
    CANCER RESEARCH, 2021, 81 (13)
  • [10] Clinical trials. A pending subject
    Gil-Extremera, B.
    Jimenez-Lopez, P.
    Mediavilla-Garcia, J. D.
    REVISTA CLINICA ESPANOLA, 2018, 218 (03): : 137 - 141
12345